Drug‐related readmissions in older hospitalized adults: External validation and updating of OPERAM DRA prediction tool

Author:

Snijders Birgitta M. G.1ORCID,Kempen Thomas G. H.23,Aubert Carole E.45ORCID,Koek Huiberdina L.1,Dalleur Olivia67,Donzé Jacques48910,Rodondi Nicolas45,O'Mahony Denis1112,Gillespie Ulrika213,Knol Wilma1

Affiliation:

1. Department of Geriatrics University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

2. Department of Pharmacy Uppsala University Uppsala Sweden

3. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

4. Department of General Internal Medicine, Bern University Hospital, Inselspital University of Bern Bern Switzerland

5. Institute of Primary Health Care (BIHAM) University of Bern Bern Switzerland

6. Clinical Pharmacy Research Group, Louvain Drug Research Institute Université Catholique de Louvain Brussels Belgium

7. Pharmacy Department Cliniques Universitaires Saint‐Luc, Université Catholique de Louvain Brussels Belgium

8. Department of Internal Medicine Neuchatel Hospital Network Neuchâtel Switzerland

9. Division of internal medicine Lausanne University Hospital, CHUV Lausanne Switzerland

10. Division of General Internal Medicine and Primary Care Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA

11. Department of Medicine (Geriatrics) University College Cork Cork Ireland

12. Department of Geriatric Medicine Cork University Hospital Cork Ireland

13. Hospital Pharmacy Department Uppsala University Uppsala Sweden

Abstract

AbstractBackgroundDrug‐related readmissions (DRAs) are defined as rehospitalizations with an adverse drug event as their main or significant contributory cause. DRAs represent a major adverse health burden for older patients. A prediction model which identified older hospitalized patients at high risk of a DRA <1 year was previously developed using the OPERAM trial cohort, a European cluster randomized controlled trial including older hospitalized patients with multimorbidity and polypharmacy. This study has performed external validation and updated the prediction model consequently.MethodsThe MedBridge trial cohort (a multicenter cluster randomized crossover trial performed in Sweden) was used as a validation cohort. It consisted of 2516 hospitalized patients aged ≥65 years. Model performance was assessed by: (1) discriminative power, assessed by the C‐statistic with a 95% confidence interval (CI); (2) calibration, assessed by visual examination of the calibration plot and use of the Hosmer–Lemeshow goodness‐of‐fit test; and (3) overall accuracy, assessed by the scaled Brier score. Several updating methods were carried out to improve model performance.ResultsIn total, 2516 older patients were included in the validation cohort, of whom 582 (23.1%) experienced a DRA <1 year. In the validation cohort, the original model showed a good overall accuracy (scaled Brier score 0.03), but discrimination was moderate (C‐statistic 0.62 [95% CI 0.59–0.64]), and calibration showed underestimation of risks. In the final updated model, the predictor “cirrhosis with portal hypertension” was removed and “polypharmacy” was added. This improved the model's discriminative capability to a C‐statistic of 0.64 (95% CI 0.59–0.70) and enhanced calibration plots. Overall accuracy remained good.ConclusionsThe updated OPERAM DRA prediction model may be a useful tool in clinical practice to estimate the risk of DRAs in older hospitalized patients subsequent to discharge. Our efforts lay the groundwork for the future development of models with even better performance.

Funder

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Geriatrics and Gerontology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3